Results 91 to 100 of about 145 (143)

[Vasodilator agents in pulmonary hypertension].

Revista medica de Chile, 1989
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Alkaloids as Vasodilator Agents: A Review

Current Pharmaceutical Design, 2023
Abstract: The pathophysiology of hypertension is often associated with endothelial dysfunction and the impairment of endothelium-dependent vasodilation mechanisms, as well as alterations in vascular smooth muscle (VSM) tone. Natural products, particularly alkaloids, have received increased attention in the search for new vasodilator agents.
Ayoub Amssayef, Mohamed Eddouks
exaly   +3 more sources

Vasodilating Agents

2015
This chapter discusses the salient features of arterial and venous dilating agents commonplace in the management of the post-cardiotomy surgical patient. A keen understanding of the underlying cellular mechanism, pharmacology, indication, safety profile, and controversies of clinical utility of vasodilating agents is imperative for routine use.
Shreyajit R. Kumar, Andrew Sosa, Ilan Margulis   +2 more
openaire   +1 more source

Positive Inotropic/Vasodilator Agents

Cardiology Clinics, 1989
Beta-adrenergic sympathomimetic agents such as dobutamine and dopamine, and phosphodiesterase inhibitors such as amrinone, milrinone, and enoxamone, exert a direct positive inotropic effect upon the myocardium by causing an increase in cyclic AMP levels. The phosphodiesterase inhibitors also exert a substantial direct vasodilator effect.
openaire   +2 more sources

Intratracheal administration of pulmonary vasodilator agents

Pediatric Pulmonology, 1992
AbstractWe compared intravenous and intratracheal administration of histamine (0.4 and 1.6 kg/kg, respectively) and nitroglycerin (5.0 and 20.0 μg/kg, respectively) in seven hypoxemic 2 week old lambs, during right lung only perfusion, to see if intratracheal administration could limit their vasodilator action to the pulmonary vessels.
M A, D'Angeli, B W, Goetzman
openaire   +2 more sources

Levosimendan, a New Inotropic and Vasodilator Agent

Anesthesiology, 2006
Several clinical studies suggest substantial limitations of currently available positive inotropic substances, including beta1-adrenoceptor agonists and phosphodiesterase III inhibitors in the short- and long-term treatment of heart failure. The reasons for these detrimental effects are related to the mechanism of action of these drugs, including ...
Wolfgang G. Toller, Christian Stranz, David C. Warltier   +2 more
openaire   +2 more sources

Vasodilators as Antihypertensive Agents

1982
In this chapter, we will analyse the mode of action and therapeutic use of the ‘direct-acting smooth muscle relaxant antihypertensor drugs’. We will include in this class of drugs those antihypertensive compounds which are supposed to relax vascular smooth muscle without interfering with identified cell receptors (adrenergic, dopaminergic, angiotensin ...
M. Worcel, J. C. Gaignault
openaire   +1 more source

The Effect of Local Vasodilating Agents

1977
Contrary to the previously widely held concept that nitroglycerin is contraindicated in acute myocardial infarction, it has recently been shown that the administration of nitroglycerin to patients with acute myocardial infarction and elevated left ventricular filling pressures results in a reduction in filling pressure and in an increase in cardiac ...
openaire   +2 more sources

β-Blocking Agents with Vasodilating Action

Journal of Cardiovascular Pharmacology, 1992
beta-Adrenoceptor-blocking drugs in current use can be separated into two main groups: those nonselective and those selective for beta 1-receptors. Members of each group reduce cardiac output and lead to an increase in peripheral resistance with a concomitant reduction in blood flow.
openaire   +2 more sources

Beta-blocking agents with vasodilator activity

Journal of Hypertension, 1993
Use of non-selective beta-blockers: Non-selective beta-blockers reduce blood pressure by reducing cardiac output. They have a proven record of efficacy, alone or in combination with other drug classes, in the treatment of hypertension, ischemic heart disease and some tachyarrhythmias.
openaire   +2 more sources